Your browser doesn't support javascript.
loading
Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide.
Krais, John J; Virani, Needa; McKernan, Patrick H; Nguyen, Quang; Fung, Kar-Ming; Sikavitsas, Vassilios I; Kurkjian, Carla; Harrison, Roger G.
Afiliación
  • Krais JJ; School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma.
  • Virani N; School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma.
  • McKernan PH; School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma.
  • Nguyen Q; School of Chemical, Biological and Materials Engineering, University of Oklahoma, Norman, Oklahoma.
  • Fung KM; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
  • Sikavitsas VI; School of Chemical, Biological and Materials Engineering, University of Oklahoma, Norman, Oklahoma.
  • Kurkjian C; Oncology/Hematology Section, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
  • Harrison RG; School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma. rharrison@ou.edu.
Mol Cancer Ther ; 16(9): 1855-1865, 2017 09.
Article en En | MEDLINE | ID: mdl-28522586
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Profármacos / Sirolimus / Ciclofosfamida / Neoplasias / Neovascularización Patológica Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Profármacos / Sirolimus / Ciclofosfamida / Neoplasias / Neovascularización Patológica Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2017 Tipo del documento: Article